Table of Contents Author Guidelines Submit a Manuscript
Neurology Research International
Volume 2011, Article ID 256460, 6 pages
http://dx.doi.org/10.1155/2011/256460
Review Article

Potential Application of Tregitopes as Immunomodulating Agents in Multiple Sclerosis

1Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, NRB 641, Boston, MA 02115, USA
2Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
3EpiVax Inc., University of Rhode Island, Providence, RI 02903, USA

Received 19 April 2011; Accepted 14 July 2011

Academic Editor: Changiz Geula

Copyright © 2011 Wassim Elyaman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. L. Weiner, “Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease,” Archives of Neurology, vol. 61, no. 10, pp. 1613–1615, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. Komiyama, S. Nakae, T. Matsuki et al., “IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis,” Journal of Immunology, vol. 177, no. 1, pp. 566–573, 2006. View at Google Scholar · View at Scopus
  3. C. L. Langrish, Y. Chen, W. M. Blumenschein et al., “IL-23 drives a pathogenic T cell population that induces autoimmune inflammation,” Journal of Experimental Medicine, vol. 201, no. 2, pp. 233–240, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Chitnis, N. Najafian, C. Benou et al., “Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis,” Journal of Clinical Investigation, vol. 108, no. 5, pp. 739–747, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Bettelli, B. Sullivan, S. J. Szabo, R. A. Sobel, L. H. Glimcher, and V. K. Kuchroo, “Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis,” Journal of Experimental Medicine, vol. 200, no. 1, pp. 79–87, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. A. E. Lovett-Racke, A. E. Rocchini, J. Choy et al., “Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes,” Immunity, vol. 21, no. 5, pp. 719–731, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. J. S. Tzartos, M. A. Friese, M. J. Craner et al., “Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis,” American Journal of Pathology, vol. 172, no. 1, pp. 146–155, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Lock, G. Hermans, R. Pedotti et al., “Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis,” Nature Medicine, vol. 8, no. 5, pp. 500–508, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Soderstrom, H. Link, J. B. Sun et al., “T cells recognizing multiple peptides of myelin basic protein are found in blood and enriched in cerebrospinal fluid in optic neuritis and multiple sclerosis,” Scandinavian Journal of Immunology, vol. 37, no. 3, pp. 355–368, 1993. View at Google Scholar · View at Scopus
  10. T. Olsson, W. W. Zhi, B. Hojeberg et al., “Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-γ,” Journal of Clinical Investigation, vol. 86, no. 3, pp. 981–985, 1990. View at Google Scholar · View at Scopus
  11. T. L. Sørensen, M. Tani, J. Jensen et al., “Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients,” Journal of Clinical Investigation, vol. 103, no. 6, pp. 807–815, 1999. View at Google Scholar · View at Scopus
  12. S. Sakaguchi, N. Sakaguchi, M. Asano, M. Itoh, and M. Toda, “Immunologic self-tolerance maintained by activated T cells expressing IL- 2 receptor α-chains (CD25). Breakdown of a single mechanism of self- tolerance causes various autoimmune diseases,” Journal of Immunology, vol. 155, no. 3, pp. 1151–1164, 1995. View at Google Scholar · View at Scopus
  13. V. Viglietta, C. Baecher-Allan, H. L. Weiner, and D. A. Hafler, “Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis,” Journal of Experimental Medicine, vol. 199, no. 7, pp. 971–979, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Haas et al., “Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis,” European Journal of Immunology, vol. 35, no. 11, pp. 3343–3352, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Venken, N. Hellings, K. Hensen et al., “Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression,” Journal of Neuroscience Research, vol. 83, no. 8, pp. 1432–1446, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Karussis, H. L. Weiner, and O. Abramsky, “Multiple sclerosis vs Lyme disease: a case presentation to a discussant and a review of the literature,” Multiple Sclerosis, vol. 5, no. 6, pp. 395–402, 1999. View at Google Scholar · View at Scopus
  17. A. S. De Groot, L. Moise, J. A. McMurry et al., “Activation of natural regulatory T cells by IgG Fc-derived peptide “Tregitopes”,” Blood, vol. 112, no. 8, pp. 3303–3311, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. A. S. de Groot and W. Martin, “Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics,” Clinical Immunology, vol. 131, no. 2, pp. 189–201, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. B. C. Schanen, A. S. de Groot, L. Moise et al., “Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4+ T cells against the swine-origin H1N1 influenza virus,” Vaccine, vol. 29, no. 17, pp. 3299–3309, 2011. View at Publisher · View at Google Scholar
  20. M. C. Eyerman, X. Zhang, and L. J. Wysocki, “T cell recognition and tolerance of antibody diversity,” Journal of Immunology, vol. 157, no. 3, pp. 1037–1046, 1996. View at Google Scholar · View at Scopus
  21. N. Soukhareva, Y. Jiang, and D. W. Scott, “Treatment of diabetes in NOD mice by gene transfer of Ig-fusion proteins into B cells: role of T regulatory cells,” Cellular Immunology, vol. 240, no. 1, pp. 41–46, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Bonifaz, D. Bonnyay, K. Mahnke, M. Rivera, M. C. Nussenzweig, and R. M. Steinman, “Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance,” Journal of Experimental Medicine, vol. 196, no. 12, pp. 1627–1638, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Jung, D. Unutmaz, P. Wong et al., “In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens,” Immunity, vol. 17, no. 2, pp. 211–220, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Théry and S. Amigorena, “The cell biology of antigen presentation in dendritic cells,” Current Opinion in Immunology, vol. 13, no. 1, pp. 45–51, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Mahnke and A. H. Enk, “Dendritic cells: key cells for the induction of regulatory T cells?” Current Topics in Microbiology and Immunology, vol. 293, pp. 133–150, 2005. View at Google Scholar · View at Scopus
  26. A. Erbacher, F. Gieseke, R. Handgretinger, and I. Müller, “Dendritic cells: functional aspects of glycosylation and lectins,” Human Immunology, vol. 70, no. 5, pp. 308–312, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. R. M. Anthony, F. Wermeling, M. C. I. Karlsson, and J. V. Ravetch, “Identification of a receptor required for the anti-inflammatory activity of IVIG,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 50, pp. 19571–19578, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. W. Elyaman, R. Bassil, A. S. De Groot et al., “Tregitopes expand regulatory T cells and ameliorate experimental autoimmune encephalomyelitis,” In Press.
  29. T. Tha-In, H. J. Metselaar, A. R. Bushell, J. Kwekkeboom, and K. J. Wood, “Intravenous immunoglobulins promote skin allograft acceptance by triggering functional activation of CD4+Foxp3+ T cells,” Transplantation, vol. 89, no. 12, pp. 1446–1455, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Lopez, M. R. Clarkson, M. Albin, M. H. Sayegh, and N. Najafian, “A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells,” Journal of the American Society of Nephrology, vol. 17, no. 10, pp. 2844–2853, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. L. J. Chi, H. B. Wang, Y. Zhang, and W. Z. Wang, “Abnormality of circulating CD4+CD25+ regulatory T cell in patients with Guillain-Barré syndrome,” Journal of Neuroimmunology, vol. 192, no. 1-2, pp. 206–214, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Sharabi, M. Dayan, H. Zinger, and E. Mozes, “A new model of induced experimental systemic lupus erythematosus (SLE) in pigs and its amelioration by treatment with a tolerogenic peptide,” Journal of Clinical Immunology, vol. 30, no. 1, pp. 34–44, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. T. Joshi, L. P. Ganesan, X. Cao, and S. Tridandapani, “Molecular analysis of expression and function of hFcγRIIbl and b2 isoforms in myeloid cells,” Molecular Immunology, vol. 43, no. 7, pp. 839–850, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. T. Smith, “Active immunity produced by so called balanced or neutral mixtures of diphtheria toxin and antitoxin,” The Journal of Experimental Medicine, vol. 11, no. 2, pp. 241–256, 1909. View at Google Scholar
  35. J. C. Cerottini, P. J. McConahey, and F. J. Dixon, “The immunosuppressive effect of passively administered antibody IgG fragments,” Journal of Immunology, vol. 102, no. 4, pp. 1008–1015, 1969. View at Google Scholar · View at Scopus
  36. F. Enriquez-Rincon and G. G. B. Klaus, “Differing effects of monoclonal anti-hapten antibodies on humoral responses to soluble or particulate antigens,” Immunology, vol. 52, no. 1, pp. 129–136, 1984. View at Google Scholar · View at Scopus
  37. S. K. Reitan and K. Hannestad, “Immunoglobulin heavy chain constant regions regulate immunity and tolerance to idiotypes of antibody variable regions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 11, pp. 7588–7593, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Kessel, H. Ammuri, R. Peri et al., “Intravenous immunoglobulin therapy affects t regulatory cells by increasing their suppressive function,” Journal of Immunology, vol. 179, no. 8, pp. 5571–5575, 2007. View at Google Scholar · View at Scopus
  39. C. N. Baxevanis, C. D. G. Ioannides, G. J. Reclos, and M. Papamichail, “Evidence for distinct epitopes on human IgG with T cell proliferative and suppressor function,” European Journal of Immunology, vol. 16, no. 8, pp. 1013–1016, 1986. View at Google Scholar · View at Scopus
  40. M. El-Amine, M. Melo, Y. Kang, H. Nguyen, J. Qian, and D. W. Scott, “Mechanisms of tolerance induction by a gene-transferred peptide-IgG fusion protein expressed in B lineage cells,” Journal of Immunology, vol. 165, no. 10, pp. 5631–5636, 2000. View at Google Scholar · View at Scopus
  41. M. El-Amine, J. A. Hinshaw, and D. W. Scott, “In vivo induction of tolerance by an lg peptide is not affected by the deletion of FcR or a mutated lgG Fc fragment,” International Immunology, vol. 14, no. 7, pp. 761–766, 2002. View at Google Scholar · View at Scopus
  42. E. T. Zambidis and D. W. Scott, “Epitope-specific tolerance induction with an engineered immunoglobulin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 10, pp. 5019–5024, 1996. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Ephrem, S. Chamat, C. Miquel et al., “Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis,” Blood, vol. 111, no. 2, pp. 715–722, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. K. Hochweller, C. H. Sweenie, and S. M. Anderton, “Immunological tolerance using synthetic peptides—basic mechanisms and clinical application,” Current Molecular Medicine, vol. 6, no. 6, pp. 631–643, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Achiron, U. Gabbay, R. Gilad et al., “Intravenous immunoglobulin treatment in multiple sclerosis: effect on relapses,” Neurology, vol. 50, no. 2, pp. 398–402, 1998. View at Google Scholar · View at Scopus
  46. Y. Shoenfeld and U. Katz, “IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients,” Autoimmunity, vol. 38, no. 2, pp. 123–137, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. R. Gold, M. Stangel, and M. C. Dalakas, “Drug Insight: the use of intravenous immunoglobulin in neurology—therapeutic considerations and practical issues,” Nature Clinical Practice Neurology, vol. 3, no. 1, pp. 36–44, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. K. L. Legge, J. J. Bell, L. Li, R. Gregg, J. C. Caprio, and H. Zaghouani, “Multi-modal antigen specific therapy for autoimmunity,” International Reviews of Immunology, vol. 20, no. 5, pp. 593–611, 2001. View at Google Scholar · View at Scopus
  49. S. Cernea, M. Dobreanu, and I. Raz, “Prevention of type 1 diabetes: today and tomorrow,” Diabetes/Metabolism Research and Reviews, vol. 26, no. 8, pp. 602–605, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. J. Nishio, M. Feuerer, J. Wong, D. Mathis, and C. Benoist, “Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor-specified peripheral niche constraints,” Journal of Experimental Medicine, vol. 207, no. 9, pp. 1879–1889, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. Grinberg-Bleyer, A. Baeyens, S. You et al., “IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells,” Journal of Experimental Medicine, vol. 207, no. 9, pp. 1871–1878, 2010. View at Publisher · View at Google Scholar · View at Scopus